Skip to content

Stress Management and Resiliency Training for Depression vs Treatment as Usual in the Treatment of Major Depression

Randomized Controlled Trial of Stress Management and Resiliency Training for Depression (SMART-D) vs Treatment as Usual in the Treatment of Major Depression

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04388748
Enrollment
27
Registered
2020-05-14
Start date
2020-12-18
Completion date
2023-05-25
Last updated
2023-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depression

Brief summary

Researchers are trying to find out if a Stress Management and Resiliency Training (SMART-D) therapy will help with major depression treatment.

Interventions

BEHAVIORALStress Management and Resiliency Training for Depression (SMART-D) Therapy

6 SMART-D group therapy sessions over 8 weeks

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
25 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Participants will be enrolled for this study from patients attending the Mayo Clinic Depression Center, Mayo Clinic Family Medicine clinics, Behavioral Health and Primary Care Clinic at Mayo Clinic Health System, Austin, MN, with a diagnosis of major depression, in partial or near remission with PHQ-9 scores ≤14 * Participants will be required to be between 25 and 80 years old * Able to speak English * Able to provide written informed consent to participate in the study * Participants must have DSM-V diagnostic confirmation of major depressive disorder (MDD) (American Psychiatric Association 2013). * Participants will continue taking any prescribed medications from their clinical treatment team. * Participants with co-morbid secondary diagnoses of persistent depressive disorder and generalized anxiety disorders will be included in the study. * Participants must consent to audio recording of random group sessions which will be disclosed at the final study session.

Exclusion criteria

* Participants with bipolar disorder, active psychosis, active suicidal ideations, and active substance abuse meeting criteria for substance use disorders except nicotine, obsessive compulsive disorder, active panic disorder with agoraphobia or other phobic disorder, active posttraumatic stress disorder, active severe personality disorders will be excluded. * Pregnant women - because of time duration of the study.

Design outcomes

Primary

MeasureTime frameDescription
Change in patient health questionnaire depression assessmentBaseline, week 1, week 8, 3 months, 6 monthsMeasured using the patient health questionnaire (PHQ-9) where total scores are reported on a scale of 1-4 Minimal depression, 5-9 Mild depression, 10-14 Moderate depression, 15-19 Moderately severe depression, 20-27 Severe depression
Change in severity of depressionBaseline, week 1, week 8, 3 months, 6 monthsMeasured using the 17 item Hamilton Depression Rating scale (HAM-D) where total scores are reported on a scale of 0 - 7 = Normal, 8 - 13 = Mild Depression, 14-18 = Moderate Depression, 19 - 22 = Severe Depression, \> 23 = Very Severe Depression

Secondary

MeasureTime frameDescription
Change in measures of resilience1 week, 8 week, 3 month, 6 monthMeasured using the Connor Davidson Resiliency Scale. Subjects are asked to indicate if they agree with 25 statements on a scale of 0=not true at all, 1=rarely true, 2=sometimes true, 3=often true and 4=true nearly all the time
Changed in perceived stress scale1 week, 8 week, 3 month, 6 monthMeasured using Perceived Stress Scale (PSS). Subjects are asked to answer a 10 question about their feelings and thoughts during the last month using a scale of 0 = Never, 1 = Almost Never, 2 = Sometimes, 3 = Fairly Often, 4 = Very Often

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026